The PRODIGE 23 trial tested a total-neoadjuvant strategy that introduced modified FOLFIRINOX before standard chemoradiotherapy, total mesorectal excision and postoperative chemotherapy in patients with locally advanced rectal cancer. The central question was whether delivering more systemic treatment before surgery could improve long-term disease control. The trial showed improved disease-free and metastasis-free outcomes with the intensified neoadjuvant strategy compared with standard treatment. These findings are particularly relevant because distant metastatic relapse remains a major challenge in rectal cancer even after technically successful surgery. For clinicians, the study reinforces the concept that systemic risk should influence treatment sequencing. Giving effective systemic therapy earlier may improve completion of treatment and reduce the chance that chemotherapy is delayed or omitted after a major pelvic operation. At the same time, the approach requires careful patient selection because treatment intensity, toxicity and functional status must be weighed against potential oncological benefit. PRODIGE 23 helped establish total-neoadjuvant therapy as a major contemporary strategy for locally advanced rectal cancer. Its practical impact is the shift toward an integrated treatment plan in which systemic therapy, radiation, imaging and surgery are deliberately sequenced around the patient's risk rather than treated as disconnected steps.